NewAmsterdam Pharma (NAMSW) Competitors $13.78 +0.34 (+2.52%) As of 08/22/2025 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock NAMSW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. NewAmsterdam Pharma vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene 180 Life Sciences (NASDAQ:ATNFW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Does the media refer more to ATNFW or NAMSW? In the previous week, NewAmsterdam Pharma had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 0 mentions for 180 Life Sciences. NewAmsterdam Pharma's average media sentiment score of 0.84 beat 180 Life Sciences' score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral NewAmsterdam Pharma Positive Is ATNFW or NAMSW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A NewAmsterdam Pharma N/A N/A N/A Which has stronger earnings and valuation, ATNFW or NAMSW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ANewAmsterdam Pharma$64.01MN/AN/AN/AN/A SummaryNewAmsterdam Pharma beats 180 Life Sciences on 3 of the 3 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMSW vs. The Competition Export to ExcelMetricNewAmsterdam PharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$137.17M$5.81B$9.76BDividend YieldN/A3.74%4.39%4.06%P/E RatioN/A3.8731.3626.05Price / SalesN/A4,053.60387.8788.42Price / CashN/A13.1938.0259.36Price / BookN/A46.309.536.60Net IncomeN/A-$90.99M$3.26B$265.65M7 Day Performance-0.15%0.64%2.14%2.00%1 Month Performance16.83%2.73%3.22%0.46%1 Year Performance99.70%203.46%30.19%18.88% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSWNewAmsterdam PharmaN/A$13.78+2.5%N/A+99.7%$0.00$64.01M0.0029ATNFW180 Life SciencesN/A$0.46-16.3%N/A+2,400.6%$0.00N/A0.007Positive NewsGap DownHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.09-10.5%N/A+174.3%$0.00$665.45K0.002Positive NewsDRTSWAlpha Tau MedicalN/A$0.27-1.1%N/AN/A$0.00N/A0.0080APLMWApollomicsN/A$0.02-8.8%N/A+24.9%$0.00N/A0.0059Positive NewsGap DownBCTXWBriaCell TherapeuticsN/A$0.03-9.7%N/A-94.8%$0.00N/A0.008Positive NewsGap UpCDIOWCardio DiagnosticsN/A$0.01+0.7%N/A-59.4%$0.00$19.90K0.007Positive NewsShort Interest ↓Gap DownCELUWCelularityN/A$0.05+9.9%N/AN/A$0.00$54.22M0.00220Positive NewsGap UpCEROWCERo TherapeuticsN/A$0.02+1.8%N/A-28.4%$0.00N/A0.008CINGWCingulateN/A$0.06-4.7%N/A-22.0%$0.00N/A0.0020CLNNWCleneN/A$0.03-6.1%N/AN/A$0.00$350K0.00100Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 60 Degrees Pharmaceuticals Alternatives Alpha Tau Medical Alternatives Apollomics Alternatives BriaCell Therapeutics Alternatives Cardio Diagnostics Alternatives Celularity Alternatives CERo Therapeutics Alternatives Cingulate Alternatives Clene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMSW) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access